Autonomic Nervous System: Introduction

Correct Answer

C — Vesicular monoamine transporter-2 blocker

Rationale

Reserpine is classified as a vesicular monoamine transporter-2 blocker. It irreversibly inhibits the vesicular monoamine transporter-2, preventing storage of dopamine, norepinephrine, and serotonin in presynaptic vesicles. The remaining options describe entirely different drug classes: acetylcholinesterase inhibitors act on cholinergic enzyme activity, monoamine oxidase inhibitors block catecholamine metabolism, and muscarinic antagonists block parasympathetic receptor signaling.

Correct Answer

A — Selective monoamine oxidase-B inhibitor

Rationale

Selegiline is a selective monoamine oxidase-B inhibitor used as an adjunct in Parkinson disease therapy. Monoamine oxidase-B preferentially metabolizes dopamine, so its inhibition increases dopamine availability in the striatum. This distinguishes selegiline from monoamine oxidase-A inhibitors such as phenelzine, which preferentially metabolize norepinephrine and serotonin and carry tyramine interaction risk. Catechol-O-methyltransferase inhibitors and acetylcholinesterase inhibitors are separate drug classes with different mechanisms and targets.

Correct Answer

D — Peripheral DOPA decarboxylase inhibitor

Rationale

Carbidopa is a peripheral DOPA decarboxylase inhibitor. It blocks the conversion of levodopa to dopamine in peripheral tissues, allowing more levodopa to reach the brain. Carbidopa does not cross the blood-brain barrier and therefore has no central effect. Tyrosine hydroxylase inhibitors block the rate-limiting step of catecholamine synthesis — metyrosine is the clinical example. Monoamine oxidase inhibitors and catechol-O-methyltransferase inhibitors block catecholamine metabolism at different enzymatic steps.

Correct Answer

B — Presynaptic blocker of acetylcholine release

Rationale

Botulinum toxin is a presynaptic blocker of acetylcholine release. It acts at the nerve terminal before the synapse, preventing vesicle fusion and exocytosis of acetylcholine. This distinguishes it from drugs acting postsynaptically on receptors or within the synaptic cleft on enzymes. Acetylcholinesterase inhibitors act within or near the cleft to block acetylcholine breakdown. Muscarinic antagonists act at postsynaptic receptors. Ganglionic blockers act at nicotinic receptors on postganglionic neurons.

Correct Answer

C — Catechol-O-methyltransferase inhibitor

Rationale

Entacapone is a catechol-O-methyltransferase inhibitor. It blocks peripheral metabolism of levodopa and dopamine by catechol-O-methyltransferase, extending the duration of levodopa effect when used alongside levodopa-carbidopa in Parkinson disease. It belongs to the same drug class as tolcapone. Monoamine oxidase inhibitors, DOPA decarboxylase inhibitors, and vesicular monoamine transporter-2 blockers are separate classes acting at different steps in catecholamine synthesis, storage, and metabolism.

Correct Answer

A — Norepinephrine transporter blocker

Rationale

Cocaine blocks the norepinephrine transporter (and the dopamine transporter), preventing reuptake of these catecholamines from the synaptic cleft and prolonging their postsynaptic effects. This reuptake-blocking mechanism produces sympathomimetic effects including tachycardia, hypertension, vasoconstriction, and mydriasis. Cocaine does not inhibit monoamine oxidase, does not block vesicular storage, and does not directly activate adrenergic receptors — its effects are indirect, mediated entirely through accumulation of endogenous catecholamines at the synapse.

Correct Answer

B — It inhibits tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis, reducing synthesis of dopamine, norepinephrine, and epinephrine

Rationale

Tyrosine hydroxylase catalyzes the conversion of tyrosine to levodopa and is the rate-limiting step in catecholamine biosynthesis. Because this is the slowest and most regulated step in the pathway, inhibiting it with metyrosine reduces production of all downstream catecholamines — dopamine, norepinephrine, and epinephrine. This makes metyrosine useful for depleting catecholamine stores preoperatively in pheochromocytoma. Reserpine blocks vesicular storage but does not reduce synthesis. Carbidopa inhibits peripheral DOPA decarboxylase — a different enzyme and a different step. Alpha-2 autoreceptors regulate release, not synthesis.

Correct Answer

D — Carbidopa inhibits peripheral DOPA decarboxylase without crossing the blood-brain barrier, allowing more levodopa to reach the brain for central conversion to dopamine

Rationale

Without carbidopa, approximately 95 percent of administered levodopa is converted to dopamine in peripheral tissues before it can cross the blood-brain barrier. Peripheral dopamine cannot enter the brain and causes nausea, vomiting, and cardiovascular side effects. Carbidopa inhibits DOPA decarboxylase in peripheral tissues but does not cross the blood-brain barrier and therefore has no central effect. By blocking peripheral conversion, carbidopa allows a much higher fraction of the levodopa dose to reach the brain, where it is converted to dopamine by central DOPA decarboxylase. Carbidopa does not cross the blood-brain barrier, does not block dopamine receptors, and does not inhibit monoamine oxidase.

Correct Answer

A — Reserpine blocks vesicular monoamine transporter-2, depleting peripheral norepinephrine stores to lower blood pressure and depleting central monoamine stores to cause depression

Rationale

Reserpine irreversibly blocks the vesicular monoamine transporter-2, preventing norepinephrine, dopamine, and serotonin from being packaged into storage vesicles. In peripheral sympathetic terminals, depletion of norepinephrine reduces vascular tone and lowers blood pressure. In the central nervous system, depletion of the same monoamine transmitters — particularly serotonin and norepinephrine — produces depression, which limits its use at the doses required for sustained blood pressure control. Reserpine does not block alpha-1 receptors, does not inhibit monoamine oxidase, and does not activate autoreceptors.

Correct Answer

C — Tyramine normally metabolized by monoamine oxidase-A in the gut and liver now accumulates, enters the circulation, and triggers massive norepinephrine release from sympathetic terminals, causing hypertensive crisis

Rationale

Tyramine is an indirect sympathomimetic amine found in fermented and aged foods. Under normal circumstances, monoamine oxidase-A in the intestinal wall and liver metabolizes dietary tyramine before it reaches the systemic circulation, so it poses no danger. When monoamine oxidase-A is inhibited by drugs such as phenelzine, tyramine escapes first-pass metabolism, enters the bloodstream, and acts as an indirect sympathomimetic — entering sympathetic nerve terminals and triggering release of stored norepinephrine. The resulting surge of norepinephrine causes a severe hypertensive crisis. Tyramine does not activate muscarinic receptors, does not produce toxic metabolites via monoamine oxidase, and does not inhibit catechol-O-methyltransferase.

Correct Answer

B — It cleaves SNARE complex proteins required for vesicle fusion, blocking calcium-triggered exocytosis of acetylcholine from cholinergic nerve terminals

Rationale

Botulinum toxin is a zinc-dependent protease that cleaves proteins of the SNARE complex — the molecular machinery required for synaptic vesicle fusion with the presynaptic membrane. Without intact SNARE proteins, calcium influx triggered by an action potential cannot drive vesicle fusion, and acetylcholine release is blocked. At the neuromuscular junction this produces flaccid muscle paralysis; in sweat gland innervation it prevents eccrine secretion. The toxin does not inhibit acetylcholinesterase, does not block postsynaptic receptors, and does not block the vesicular acetylcholine transporter — it acts specifically on the release machinery before exocytosis.

Correct Answer

D — Alpha-2 autoreceptors on sympathetic terminals detect norepinephrine in the cleft and reduce further release as negative feedback; clonidine activates central alpha-2 receptors to reduce overall sympathetic outflow

Rationale

Alpha-2 adrenergic receptors on presynaptic sympathetic nerve terminals serve as autoreceptors — they sense norepinephrine accumulation in the synaptic cleft and, when activated, inhibit further norepinephrine release through a Gi-mediated mechanism that reduces cyclic adenosine monophosphate and limits calcium influx. This negative feedback prevents excessive norepinephrine accumulation. Clonidine is an alpha-2 agonist that, when taken systemically, acts on alpha-2 receptors in the brainstem to reduce central sympathetic outflow, lowering blood pressure and heart rate. It does not respond to acetylcholine, is not exclusively postsynaptic, and does not interact with vesicular storage.

Correct Answer

A — Reuptake into the presynaptic terminal via the norepinephrine transporter

Rationale

The norepinephrine transporter on the presynaptic membrane is the primary mechanism for terminating norepinephrine signaling at sympathetic synapses — it actively transports norepinephrine back into the nerve terminal, where it can be repackaged into vesicles or degraded by monoamine oxidase. This reuptake accounts for approximately 70 to 80 percent of synaptic norepinephrine clearance. Drugs that block the norepinephrine transporter — including cocaine, tricyclic antidepressants, and atomoxetine — prolong norepinephrine's presence in the cleft and amplify sympathomimetic effects. Acetylcholinesterase degrades acetylcholine, not norepinephrine. Monoamine oxidase and catechol-O-methyltransferase are secondary metabolic pathways; reuptake via the norepinephrine transporter accounts for the majority of synaptic clearance.

Correct Answer

C — Amphetamine enters the terminal via the norepinephrine transporter, reverses the direction of that transporter, and also disrupts vesicular storage, causing non-exocytotic norepinephrine release independent of calcium or action potentials

Rationale

Amphetamine is a substrate for the norepinephrine transporter and enters the presynaptic terminal through it. Once inside, amphetamine reverses the transporter's direction so that it pumps norepinephrine out of the terminal into the cleft rather than inward. Amphetamine also disrupts vesicular monoamine transporter-2, releasing norepinephrine from storage vesicles into the cytoplasm for subsequent efflux. This mechanism is non-exocytotic and does not require calcium influx or action potentials — which explains why amphetamine can release catecholamines even when nerve firing is suppressed. Option D describes reuptake inhibition, which is the mechanism of cocaine and tricyclic antidepressants, not amphetamine. Amphetamine does not directly activate adrenergic receptors and does not primarily work by inhibiting monoamine oxidase.

Correct Answer

B — Carbidopa inhibits peripheral DOPA decarboxylase, reducing conversion of levodopa to dopamine outside the brain and allowing more levodopa to reach the striatum

Rationale

Without carbidopa, the enzyme DOPA decarboxylase in the intestinal wall, liver, and peripheral tissues converts most of the levodopa dose to dopamine before it can cross the blood-brain barrier. Peripheral dopamine cannot enter the brain and instead causes nausea and cardiovascular stimulation. By inhibiting this peripheral enzyme, carbidopa spares levodopa from premature conversion, dramatically increasing the fraction that reaches the brain for central conversion to dopamine in the striatum. Carbidopa does not cross the blood-brain barrier and has no central effect. It does not block dopamine receptors and does not inhibit monoamine oxidase.

Correct Answer

D — Phenelzine inhibits monoamine oxidase-A in the gut and liver, allowing dietary tyramine to escape first-pass metabolism, enter the circulation, and trigger massive norepinephrine release from sympathetic terminals

Rationale

Tyramine is an indirect sympathomimetic found in aged and fermented foods. Normally, monoamine oxidase-A in the intestinal wall and liver metabolizes dietary tyramine during first-pass metabolism so it never reaches systemic circulation in significant quantities. When monoamine oxidase-A is inhibited by phenelzine, tyramine escapes this metabolic barrier, enters the bloodstream, and acts as an indirect sympathomimetic — entering sympathetic terminals via the norepinephrine transporter and triggering non-exocytotic release of stored norepinephrine. The resulting catecholamine surge produces severe hypertension, headache, and diaphoresis. Phenelzine does not directly activate adrenergic receptors, tyramine does not produce toxic metabolites via monoamine oxidase, and this interaction does not involve the norepinephrine transporter being saturated.

Correct Answer

A — Phenoxybenzamine irreversibly blocks alpha adrenergic receptors, preventing the severe hypertension that would result from catecholamine release during surgical manipulation of the tumor

Rationale

Phenoxybenzamine is a non-selective, irreversible alpha adrenergic antagonist. When given preoperatively, it establishes sustained alpha blockade that cannot be overcome even if the surgical team accidentally squeezes the tumor and triggers a massive catecholamine surge. The irreversibility of phenoxybenzamine is the key pharmacological feature that makes it suitable for this indication — a competitive alpha blocker could be overwhelmed by the high catecholamine concentrations released during tumor manipulation. Preoperative alpha blockade is always established before beta blockers are added, because blocking beta receptors without first blocking alpha receptors in a catecholamine-excess state can produce paradoxical hypertension. Phenoxybenzamine does not inhibit tyrosine hydroxylase, does not block beta receptors, and does not act on vesicular storage.

Correct Answer

C — Reserpine blocks vesicular monoamine transporter-2 in central neurons, depleting stores of norepinephrine, dopamine, and serotonin and reducing monoaminergic transmission

Rationale

Reserpine irreversibly blocks the vesicular monoamine transporter-2 throughout the body, including in central nervous system neurons. When vesicles can no longer concentrate monoamine neurotransmitters, norepinephrine, dopamine, and serotonin leak into the cytoplasm and are degraded by monoamine oxidase. Over days to weeks this depletes central monoamine stores, reducing the monoaminergic transmission that sustains mood, motivation, and drive. The resulting syndrome resembles major depression and was one of the early observations that linked low monoamine activity to depressive states — the foundation of the monoamine hypothesis of depression. Reserpine does not inhibit monoamine oxidase, does not block alpha-2 autoreceptors, and does not act on the norepinephrine reuptake transporter.